Table 4.

Long-term cost-effectiveness outcomes in the base-case analysis

Health outcomes	Once-weekly semaglutide 1 mg	Liraglutide 1.2 mg	Difference
Discounted life expectancy (years)	12.41 (0.13)	12.29 (0.13)	+ 0.12
Discounted quality-adjusted life expectancy (QALYs)	7.77 (0.08)	7.64 (0.08)	+ 0.13
Discounted direct costs (EUR)	25,183 (795)	25,116 (881)	+ 67
ICER based on life expectancy and direct costs	EUR 561 per life year gained
ICER based on quality-adjusted life expectancy and direct costs	EUR 523 per QALY gained

Values are means (standard deviations)

EUR euros, ICER incremental cost-effectiveness ratio, QALYs quality-adjusted life years